Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Gene Start-Up Sloning Raises $3.7M in VC Cash; Manufacturing Plant to Open 06

NEW YORK, July 8 (GenomeWeb News) - Synthetic gene company Sloning BioTechnology has raised €3.1 million ($3.7 million) in private equity, the company said.


The investment, originally made in May, was from Swiss VC shop HBM BioVentures and German company KFW Mittelstandsbank.


Sloning, based in Munich, Germany, said the cash will help it build its first production pant for synthetic genes. The plant, which will be developed with Accelab Laborautomations, is expected to be fully operational by mid-2006.


Additional details were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.